ProCE Banner Activity

Optimal Treatment Combinations in the Management of CLL/SLL

Clinical Thought

Read this expert commentary on the optimal combination strategies in the treatment of patients with CLL/SLL

Released: November 22, 2022

Expiration: November 21, 2023

No longer available for credit.

Share

Faculty

Jeffrey P. Sharman

Jeffrey P. Sharman, MD

Medical Director of Hematology Research
Sarah Cannon at Willamette Valley Cancer Institute
Eugene, Oregon

Provided by

Provided by Clinical Care Options, LLC

ProCE Banner

Supporters

Supported by educational grants from

AbbVie Inc.

AstraZeneca Pharmaceuticals

Lilly

Faculty Disclosure

Primary Author

Jeffrey P. Sharman, MD

Medical Director of Hematology Research
Sarah Cannon at Willamette Valley Cancer Institute
Eugene, Oregon

Jeffrey P. Sharman, MD: consultant/advisor/speaker: AbbVie, ADC Therapeutics, AstraZeneca, BeiGene, Bristol Myers Squibb, Genentech, Janssen, Lilly, Merck.